AZN Jul 2024 79.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:33PM EDT. Market open.
| Previous Close | 0.5200 |
| Open | 0.7700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 79.00 |
| Expire Date | 2024-07-12 |
| Day's Range | 0.4600 - 0.7800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ReutersAstraZeneca's COVID prevention drug application gets EU fast-track assessment
"The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said. An accelerated assessment aims to speed up the EMA's review of a market authorisation application. AstraZeneca acquired sipavibart from RQ Bio in May 2022.
ZacksWhy Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZacksPharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
© 2024 Yahoo. All rights reserved.